Events
The Frankfurt Foundation Quality of Medicines (FFQM) plans to organize events on current issues relating to quality of medicinal products and its optimization, for example in the form of expert discussions or press conferences. In this way, attention should be drawn to the importance of the respective problems and the dialogue in specialist circles. As well the exchange with political institutions should be initiated or intensified. Another goal is to provide the public with competent information on quality of medicinal products.
August 4, 2026
Expertmeeting „Pharmaceutical Analytics—Current Status and Outlook(s): Small Molecules, Biotech Products & Nanomedicines“
On July 16, 2026, experts from academia, industry, and government agencies gathered at the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) in Frankfurt am Main for the expert meeting titled “Pharmaceutical Analytics—Current Status and Outlook(s): Small Molecules, Biotech Products & Nanomedicines.” The event was hosted by the House of Pharma & Healthcare and the Frankfurt Foundation Quality of Medicines. Prof. Dr. Manfred Schubert-Zsilavecz and Prof. Dr. Henning Blume opened the meeting on behalf of the two institutions. Discussions focused on current analytical and regulatory challenges for ensuring the quality of finished pharmaceutical products throughout their entire product lifecycle. The central question was how pharmaceutical analytics can continue to guarantee quality, safety, and trust in the face of increasingly complex products, manufacturing processes, and data volumes.
High-resolution mass spectrometry and other modern techniques enable increasingly precise characterization of molecular structure, even for highly complex pharmaceuticals such as biologics and nanomedicines. However, as analytical capabilities expand, a tension arises between technological progress and regulatory classification. What is technically possible is not necessarily relevant to quality assurance. At the same time, established regulatory requirements may not be sufficient to adequately address all new risks associated with these complex product classes.
Moderated by Prof. Dr. Manfred Schubert-Zsilavecz and Prof. Dr. Stefanie Kaiser, participants from universities, pharmaceutical manufacturers, and regulatory agencies discussed how to address the future opportunities and challenges in pharmaceutical analytics.
A statement titled “Pharmaceutical Analytics—A Cornerstone of Quality Control” is currently being prepared; it summarizes the key findings and conclusions, as well as the resulting recommendations and calls for action from the expert panel. The statement is currently being reviewed and finalized with the meeting participants.
